ACAD Q2 2018 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+87.2% YoY

Gross Profit

$52M91.1% margin

Operating Income

-$64M-112.3% margin

Net Income

-$63M-110.9% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+16.8%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$315M

Total Liabilities

$50M

Stockholders' Equity

$265M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$30M	+87.2%
Gross Profit	$52M	$27M	+90.6%
Operating Income	-$64M	-$68M	+6.4%
Net Income	-$63M	-$67M	+6.2%